Diabetic Ketoacidosis Lab Diagnosis: A Comprehensive Guide

Introduction

Diabetic ketoacidosis (DKA) is a severe and potentially life-threatening complication of diabetes mellitus, marked by a trio of uncontrolled hyperglycemia, metabolic acidosis, and elevated ketone body concentrations. Predominantly observed in individuals with type 1 diabetes, DKA can also manifest in those with type 2 diabetes under certain conditions. This crisis arises from a deficiency in insulin, either absolute or relative, which is exacerbated by the physiological stresses of hyperglycemia, dehydration, and acidosis. Often, DKA is precipitated by factors such as infections, the onset of new diabetes, or non-adherence to prescribed treatment regimens. Accurate and timely Diabetic Ketoacidosis Lab Diagnosis is paramount for effective management and to mitigate adverse outcomes. This article delves into the critical role of laboratory evaluations in diagnosing DKA, outlining the essential tests, result interpretation, and their significance in patient care.

Understanding Diabetic Ketoacidosis

Diabetic ketoacidosis is characterized by a complex interplay of metabolic derangements stemming from insulin deficiency. To effectively understand the diabetic ketoacidosis lab diagnosis, it’s crucial to grasp the underlying etiology and pathophysiology of this condition.

Etiology of DKA

DKA primarily affects individuals with type 1 diabetes due to their absolute insulin deficiency, but it’s increasingly recognized in type 2 diabetes patients as well, especially under conditions of severe insulin stress. Several factors can precipitate DKA, including:

• Infections: Pneumonia and urinary tract infections are the most common infectious triggers.
• New-onset diabetes: Often, DKA is the presenting manifestation of previously undiagnosed type 1 diabetes.
• Non-compliance with insulin therapy: Missed insulin doses or inadequate insulin administration in known diabetics.
• Acute illnesses and stressors: Trauma, surgery, myocardial infarction, and pulmonary embolism can trigger DKA.
• Certain medications: Corticosteroids, thiazide diuretics, sympathomimetic agents, pentamidine, and even some antipsychotic drugs can disrupt carbohydrate metabolism and lead to DKA.
• SGLT2 inhibitors: This class of drugs, while beneficial for glycemic control, can paradoxically increase the risk of euglycemic DKA, where ketoacidosis occurs with only mildly elevated or even normal blood glucose levels.
• Substance abuse: Alcohol and cocaine abuse have been linked to increased risk of DKA, particularly recurrent episodes.

Pathophysiology of DKA

The metabolic cascade in DKA is initiated by insulin deficiency and an increase in counter-regulatory hormones (glucagon, catecholamines, cortisol, and growth hormone). This hormonal imbalance leads to:

• Hyperglycemia: Reduced glucose uptake by peripheral tissues and increased hepatic glucose production (gluconeogenesis and glycogenolysis) result in elevated blood glucose levels.
• Ketogenesis: Insulin deficiency promotes lipolysis, releasing free fatty acids. In the liver, these fatty acids are converted to ketone bodies (beta-hydroxybutyrate, acetoacetate, and acetone) as an alternative energy source. The overproduction of ketone bodies leads to ketonemia and metabolic acidosis.
• Metabolic Acidosis: The accumulation of ketone bodies, which are acidic, overwhelms the body’s buffering capacity, leading to a decrease in blood pH and metabolic acidosis.
• Dehydration and Electrolyte Imbalance: Hyperglycemia-induced osmotic diuresis leads to significant fluid and electrolyte loss, including sodium, potassium, phosphate, and magnesium. Despite serum potassium levels often appearing normal or even elevated initially due to extracellular shift from acidosis, total body potassium is depleted. Hyperosmolarity contributes to altered mental status, a hallmark of severe DKA.
• Inflammatory Response: Hyperglycemia itself can induce a pro-inflammatory state, further complicating the clinical picture.

Understanding these pathophysiological mechanisms is essential for interpreting the results of diabetic ketoacidosis lab diagnosis and guiding appropriate therapeutic interventions.

The Crucial Role of Laboratory Diagnosis in DKA

Laboratory diagnosis is not just an adjunct but a cornerstone in the management of diabetic ketoacidosis. Rapid and accurate diabetic ketoacidosis lab diagnosis is critical for several reasons:

1. Confirmation of Diagnosis: Clinical symptoms of DKA can be varied and sometimes overlap with other conditions. Lab tests provide objective evidence to confirm the diagnosis of DKA, differentiating it from other causes of metabolic acidosis or altered mental status.
2. Assessment of Severity: The degree of hyperglycemia, acidosis, and ketonemia, as revealed by lab tests, helps in assessing the severity of DKA. This stratification guides the intensity of treatment and helps predict prognosis.
3. Guiding Treatment: Lab values are crucial for monitoring the response to treatment. Serial measurements of blood glucose, electrolytes, blood gases, and ketone levels are essential to adjust insulin and fluid therapy, ensuring effective and safe correction of metabolic derangements.
4. Monitoring for Complications: Electrolyte imbalances, a major concern in DKA, are identified and monitored through lab tests. Timely electrolyte replacement, guided by lab results, is vital to prevent life-threatening complications like cardiac arrhythmias.
5. Differential Diagnosis: Lab findings are instrumental in ruling out other conditions that may mimic DKA, such as hyperosmolar hyperglycemic state (HHS), alcoholic ketoacidosis, or other causes of metabolic acidosis.

In essence, diabetic ketoacidosis lab diagnosis provides the quantitative data necessary for accurate diagnosis, risk stratification, treatment guidance, and monitoring, all of which are indispensable for optimizing patient outcomes in DKA.

Key Laboratory Tests for DKA Diagnosis

A comprehensive panel of laboratory tests is required for the accurate diagnosis and management of DKA. These tests can be broadly categorized based on what they measure and their specific role in DKA assessment.

Blood Glucose Measurement

• Purpose: To confirm hyperglycemia, a primary criterion for DKA diagnosis.
• Normal Range: 70-100 mg/dL (fasting), <140 mg/dL (2-hour postprandial).
• DKA Diagnostic Threshold: Typically, blood glucose levels in DKA are greater than 250 mg/dL. However, it’s important to note that in euglycemic DKA, glucose levels may be less than 250 mg/dL, sometimes even within the normal range.
• Clinical Significance: Elevated blood glucose confirms hyperglycemia. The level itself does not directly correlate with the severity of acidosis but is a key diagnostic criterion and needs to be monitored frequently during treatment. Point-of-care testing (POCT) for glucose is essential for hourly monitoring in the acute phase of DKA management.

Arterial Blood Gas (ABG) Analysis

• Purpose: To assess acid-base status, specifically to detect and quantify metabolic acidosis, a hallmark of DKA.
• Key Parameters:
  • pH: Normal range: 7.35-7.45. In DKA, arterial pH is typically less than 7.3, indicating acidosis. Severe DKA may present with pH < 7.0.
  • Bicarbonate (HCO3-): Normal range: 22-28 mEq/L. In DKA, serum bicarbonate is reduced, usually below 15 mEq/L, reflecting the buffering of ketoacids. Levels can drop to very low values in severe DKA.
  • Partial pressure of carbon dioxide (pCO2): Normal range: 35-45 mmHg. In DKA, pCO2 may be low due to compensatory respiratory alkalosis (Kussmaul breathing), as the body attempts to reduce acidosis by blowing off CO2.
  • Anion Gap: Calculated as [Na+] – ([Cl-] + [HCO3-]). Normal range: 8-12 mEq/L (or 10-18 mEq/L with potassium). In DKA, the anion gap is elevated (>12 mEq/L, often >14-15 mEq/L) due to the accumulation of unmeasured anions, primarily ketone bodies.
• Clinical Significance: ABG analysis is critical for diagnosing metabolic acidosis and assessing its severity. The degree of acidosis (pH and bicarbonate levels) is a key criterion for DKA diagnosis and for monitoring treatment response. The anion gap helps confirm the presence of increased unmeasured anions (ketoacids).

Ketone Body Measurement

• Purpose: To detect and quantify ketonemia or ketonuria, confirming the presence of excessive ketone bodies, another cardinal feature of DKA.
• Methods:
  • Urine Ketones: Traditionally measured using nitroprusside reagent strips. These tests primarily detect acetoacetate and acetone, but are less sensitive to beta-hydroxybutyrate, the predominant ketone body in DKA. Urine ketone tests can be qualitative (trace, small, moderate, large) or semi-quantitative.
  • Serum Ketones:
    • Nitroprusside Test (Acetest tablets): Similar to urine tests, primarily detects acetoacetate and acetone.
    • Beta-hydroxybutyrate (β-HB) Assay: Quantitative assays for β-HB are now readily available and are preferred for diagnosing and monitoring DKA. They provide a more accurate reflection of total ketone body concentration and are not affected by redox state changes that can influence acetoacetate levels.
• Normal Range: Ketones are normally present in trace amounts. In DKA, ketone levels are significantly elevated.
• Clinical Significance: The presence of moderate to large ketones in urine or elevated serum ketone levels (especially β-HB) is a key diagnostic criterion for DKA. Quantitative β-HB measurements are particularly useful for monitoring treatment efficacy, as β-HB levels decrease earlier than acetoacetate during successful DKA resolution. The traditional nitroprusside test may underestimate the severity of ketosis and can sometimes give false positives.

Electrolyte Panel

• Purpose: To assess for electrolyte imbalances, which are common and potentially life-threatening in DKA.
• Key Electrolytes:
  • Sodium (Na+): Serum sodium levels may be falsely low in DKA due to hyperglycemia-induced osmotic shift of water from intracellular to extracellular space. Corrected sodium should be calculated: Corrected Na+ = Measured Na+ + [1.6 x (Glucose – 100) / 100]. True hyponatremia may also occur due to sodium losses in urine. Hypernatremia is less common but can occur with severe dehydration.
  • Potassium (K+): Serum potassium levels can be normal, elevated, or low at presentation. Despite the serum level, total body potassium is usually depleted due to urinary losses. Insulin therapy drives potassium intracellularly, often leading to hypokalemia.
  • Chloride (Cl-): Hyperchloremia may develop, especially with normal saline resuscitation, potentially contributing to hyperchloremic metabolic acidosis.
  • Bicarbonate (HCO3-): Already assessed in ABG, also part of the electrolyte panel.
  • Magnesium (Mg2+): Hypomagnesemia is common in DKA and can exacerbate hypokalemia and cardiac arrhythmias.
  • Phosphate (PO43-): Hypophosphatemia is also common, although serum phosphate levels may initially be normal or even elevated. Phosphate levels can drop precipitously with insulin therapy.
• Clinical Significance: Electrolyte imbalances, particularly potassium and magnesium, are major concerns in DKA management. Monitoring and replacing these electrolytes is crucial to prevent cardiac arrhythmias, muscle weakness, and respiratory failure. Corrected sodium should be used to interpret sodium levels accurately.

Osmolality

• Purpose: To assess serum osmolality, which is often elevated in DKA due to hyperglycemia and hypernatremia, contributing to neurological symptoms.
• Calculation: Serum Osmolality (mOsm/kg) = 2[Na+ (mEq/L) + K+ (mEq/L)] + Glucose (mg/dL)/18 + BUN (mg/dL)/2.8. Simplified approximation: 2[Na+ (mEq/L)] + Glucose (mg/dL)/18.
• Normal Range: 275-295 mOsm/kg.
• Clinical Significance: Elevated serum osmolality (>295 mOsm/kg, often >320 mOsm/kg in severe cases) contributes to dehydration and altered mental status. Monitoring osmolality can help assess the severity of hyperosmolar state, although it is more pronounced in Hyperosmolar Hyperglycemic State (HHS) than in typical DKA.

Other Relevant Laboratory Tests

• Blood Urea Nitrogen (BUN) and Creatinine: To assess renal function, which may be impaired due to dehydration. Elevated BUN and creatinine levels indicate pre-renal azotemia.
• Complete Blood Count (CBC): Leukocytosis is common in DKA, even without infection, due to stress response. However, it’s important to evaluate for signs of infection, as infection is a common precipitating factor.
• Glycated Hemoglobin (HbA1c): Provides information about long-term glycemic control over the past 2-3 months. Useful in distinguishing new-onset diabetes from pre-existing diabetes and assessing chronic glycemic control.
• Serum Amylase and Lipase: May be elevated in DKA, even in the absence of pancreatitis. Markedly elevated lipase, especially with severe abdominal pain, should prompt consideration of pancreatitis, but mild to moderate elevations can be seen in DKA alone.

Interpreting Lab Results for DKA Diagnosis

The diagnosis of DKA is based on a constellation of clinical and laboratory findings. According to the American Diabetes Association (ADA) criteria, DKA is typically diagnosed when the following lab criteria are met:

• Blood Glucose: > 250 mg/dL (though may be <250 mg/dL in euglycemic DKA)
• Arterial pH: < 7.3 or Venous pH < 7.35
• Serum Bicarbonate: < 15 mEq/L
• Anion Gap: > 12 mEq/L
• Ketonemia or Ketonuria: Presence of moderate or large ketones in serum or urine.

It’s crucial to interpret lab results in the clinical context. A patient presenting with symptoms of hyperglycemia, dehydration, and altered mental status, along with the above lab findings, is highly likely to have DKA.

Severity Assessment based on Lab Values:

DKA severity can be classified based on the degree of acidosis:

• Mild DKA: pH 7.25-7.30, Bicarbonate 15-18 mEq/L, Anion Gap > 12 mEq/L, Ketones positive, Alert mental status.
• Moderate DKA: pH 7.00-7.24, Bicarbonate 10-14 mEq/L, Anion Gap > 12 mEq/L, Ketones positive, May be drowsy.
• Severe DKA: pH < 7.00, Bicarbonate < 10 mEq/L, Anion Gap > 12 mEq/L, Ketones positive, Stupor or coma may be present.

These severity criteria, along with clinical assessment, guide the intensity of monitoring and treatment.

Monitoring DKA with Lab Tests

Once DKA is diagnosed and treatment initiated, frequent laboratory monitoring is essential to assess response to therapy and guide ongoing management. Key parameters to monitor and frequency of testing include:

• Hourly Point-of-Care Glucose: To track glucose response to insulin therapy. Target glucose reduction is typically 50-70 mg/dL per hour.
• Electrolyte Panel (including potassium, sodium, chloride, bicarbonate, magnesium, phosphate): Initially every 1-2 hours until stable, then every 2-4 hours. Potassium levels are particularly critical and require close monitoring and replacement.
• Venous Blood Gas (VBG) or Arterial Blood Gas (ABG): Initially every 1-2 hours until pH and bicarbonate improve, then less frequently as acidosis resolves. VBG is often sufficient for monitoring pH and bicarbonate unless respiratory compromise is present.
• Serum Ketones (β-HB): Can be monitored every 2-4 hours initially, then less frequently as levels decrease. Quantitative β-HB assays are helpful for tracking ketosis resolution.
• BUN and Creatinine: Daily, to monitor renal function.
• Serum Osmolality: If significant hyperosmolarity is suspected or altered mental status persists.
• Urine Output: Closely monitor to assess hydration status and renal perfusion.

Frequency of lab monitoring should be adjusted based on the patient’s clinical condition and response to treatment. As DKA resolves, the frequency of testing can be reduced. Resolution of DKA is defined by:

• Blood Glucose: < 200 mg/dL
• Venous pH: > 7.3
• Serum Bicarbonate: ≥ 15 mEq/L
• Anion Gap: ≤ 12 mEq/L
• Clinical Improvement: Patient is able to eat and tolerate oral fluids, mental status improved.

Differential Diagnosis and Lab Findings

While diabetic ketoacidosis lab diagnosis relies on specific criteria, it’s important to differentiate DKA from other conditions that may present with similar symptoms or lab abnormalities. Key differential diagnoses and how lab findings help distinguish them include:

• Hyperosmolar Hyperglycemic State (HHS): HHS is another hyperglycemic emergency in diabetes, but with less ketosis and more profound hyperosmolarity and dehydration.
  • Lab Differences: In HHS, blood glucose is typically much higher (>600 mg/dL), serum osmolality is significantly elevated (>320 mOsm/kg), and acidosis and ketonemia are mild or absent. pH is usually >7.3, bicarbonate >15 mEq/L, and anion gap may be normal or slightly elevated.
• Alcoholic Ketoacidosis (AKA): Occurs in chronic alcohol users, often after binge drinking and starvation.
  • Lab Differences: In AKA, blood glucose may be low, normal, or mildly elevated. Ketosis and acidosis are present, but the ratio of β-hydroxybutyrate to acetoacetate is often higher than in DKA. History of alcohol abuse is crucial.
• Starvation Ketosis: Prolonged fasting can lead to mild ketosis.
  • Lab Differences: Ketosis is mild, blood glucose is low or normal, and acidosis is minimal or absent. pH and bicarbonate are usually within normal limits or only slightly altered. Anion gap is mildly elevated.
• Lactic Acidosis: Can be caused by sepsis, shock, severe hypoxia, or certain medications.
  • Lab Differences: Lactic acidosis presents with elevated lactate levels (>4 mmol/L). Blood glucose may be variable, ketosis is usually absent, and anion gap acidosis is present. Lactate measurement is key to differentiation.
• Toxic Ingestions (e.g., ethylene glycol, methanol, salicylate): Can cause anion gap metabolic acidosis.
  • Lab Differences: Specific toxicological assays are needed for diagnosis. Clinical history of ingestion is important. Ethylene glycol and methanol may cause elevated osmol gap, while salicylate ingestion can present with mixed acid-base disturbances and salicylate levels are elevated.
• Uremia (Renal Failure): Severe renal failure can cause metabolic acidosis with elevated BUN and creatinine.
  • Lab Differences: No significant hyperglycemia or ketonemia. Acidosis is due to impaired renal acid excretion. Chronically elevated BUN and creatinine levels are characteristic.

Careful interpretation of the complete lab panel, along with clinical context, is essential for accurate differential diagnosis.

Conclusion

Diabetic ketoacidosis lab diagnosis is an indispensable component of managing this critical condition. A comprehensive panel of tests, including blood glucose, arterial blood gas analysis, ketone body measurement, electrolyte panel, and osmolality, is crucial for confirming the diagnosis, assessing severity, guiding treatment, and monitoring response. Understanding the significance of each lab parameter and its interpretation in the clinical context is vital for healthcare professionals involved in the care of patients with DKA. Rapid and accurate diabetic ketoacidosis lab diagnosis, combined with prompt and appropriate treatment, significantly improves outcomes and reduces morbidity and mortality associated with this potentially life-threatening diabetic emergency.

References

1. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009 Jul;32(7):1335-43.
2. Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab. 2015 Aug;100(8):2849-52.
3. Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. Endocrinol Diabetes Metab Case Rep. 2017;2017.
4. Gosmanov AR, Kitabchi AE. Diabetic Ketoacidosis. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. MDText.com, Inc.; South Dartmouth (MA): Apr 28, 2018.
5. Fazeli Farsani S, Brodovicz K, Soleymanlou N, Marquard J, Wissinger E, Maiese BA. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review. BMJ Open. 2017 Aug 01;7(7):e016587.
6. Große J, Hornstein H, Manuwald U, Kugler J, Glauche I, Rothe U. Incidence of Diabetic Ketoacidosis of New-Onset Type 1 Diabetes in Children and Adolescents in Different Countries Correlates with Human Development Index (HDI): An Updated Systematic Review, Meta-Analysis, and Meta-Regression. Horm Metab Res. 2018 Mar;50(3):209-222.
7. Wachtel TJ, Tetu-Mouradjian LM, Goldman DL, Ellis SE, O’Sullivan PS. Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island. J Gen Intern Med. 1991 Nov-Dec;6(6):495-502.
8. Umpierrez GE, Kelly JP, Navarrete JE, Casals MM, Kitabchi AE. Hyperglycemic crises in urban blacks. Arch Intern Med. 1997 Mar 24;157(6):669-75.
9. Benoit SR, Zhang Y, Geiss LS, Gregg EW, Albright A. Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality – United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):362-365.
10. Wang J, Williams DE, Narayan KM, Geiss LS. Declining death rates from hyperglycemic crisis among adults with diabetes, U.S., 1985-2002. Diabetes Care. 2006 Sep;29(9):2018-22.
11. Gaglia JL, Wyckoff J, Abrahamson MJ. Acute hyperglycemic crisis in the elderly. Med Clin North Am. 2004 Jul;88(4):1063-84, xii.
12. Philippe J. Insulin regulation of the glucagon gene is mediated by an insulin-responsive DNA element. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7224-7.
13. Barnes AJ, Bloom SR, Goerge K, Alberti GM, Smythe P, Alford FP, Chisholm DJ. Ketoacidosis in pancreatectomized man. N Engl J Med. 1977 Jun 02;296(22):1250-3.
14. Fulop M, Tannenbaum H, Dreyer N. Ketotic hyperosmolar coma. Lancet. 1973 Sep 22;2(7830):635-9.
15. Umpierrez G, Freire AX. Abdominal pain in patients with hyperglycemic crises. J Crit Care. 2002 Mar;17(1):63-7.
16. Lorber D. Nonketotic hypertonicity in diabetes mellitus. Med Clin North Am. 1995 Jan;79(1):39-52.
17. Umpierrez GE, Khajavi M, Kitabchi AE. Review: diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Am J Med Sci. 1996 May;311(5):225-33.
18. Paulson WD, Gadallah MF. Diagnosis of mixed acid-base disorders in diabetic ketoacidosis. Am J Med Sci. 1993 Nov;306(5):295-300.
19. Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, Wall BM. Management of hyperglycemic crises in patients with diabetes. Diabetes Care. 2001 Jan;24(1):131-53.
20. Molitch ME, Rodman E, Hirsch CA, Dubinsky E. Spurious serum creatinine elevations in ketoacidosis. Ann Intern Med. 1980 Aug;93(2):280-1.
21. Warshaw AL, Feller ER, Lee KH. On the cause of raised serum-amylase in diabetic ketoacidosis. Lancet. 1977 Apr 30;1(8018):929-31.
22. Vantyghem MC, Haye S, Balduyck M, Hober C, Degand PM, Lefebvre J. Changes in serum amylase, lipase and leukocyte elastase during diabetic ketoacidosis and poorly controlled diabetes. Acta Diabetol. 1999 Jun;36(1-2):39-44.
23. Weidman SW, Ragland JB, Fisher JN, Kitabchi AE, Sabesin SM. Effects of insulin on plasma lipoproteins in diabetic ketoacidosis: evidence for a change in high density lipoprotein composition during treatment. J Lipid Res. 1982 Jan;23(1):171-82.
24. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD000567.
25. Mahler SA, Conrad SA, Wang H, Arnold TC. Resuscitation with balanced electrolyte solution prevents hyperchloremic metabolic acidosis in patients with diabetic ketoacidosis. Am J Emerg Med. 2011 Jul;29(6):670-4.
26. Chua HR, Venkatesh B, Stachowski E, Schneider AG, Perkins K, Ladanyi S, Kruger P, Bellomo R. Plasma-Lyte 148 vs 0.9% saline for fluid resuscitation in diabetic ketoacidosis. J Crit Care. 2012 Apr;27(2):138-45.
27. Van Zyl DG, Rheeder P, Delport E. Fluid management in diabetic-acidosis–Ringer’s lactate versus normal saline: a randomized controlled trial. QJM. 2012 Apr;105(4):337-43.
28. Adrogué HJ, Barrero J, Eknoyan G. Salutary effects of modest fluid replacement in the treatment of adults with diabetic ketoacidosis. Use in patients without extreme volume deficit. JAMA. 1989 Oct 20;262(15):2108-13.
29. Edge JA, Jakes RW, Roy Y, Hawkins M, Winter D, Ford-Adams ME, Murphy NP, Bergomi A, Widmer B, Dunger DB. The UK case-control study of cerebral oedema complicating diabetic ketoacidosis in children. Diabetologia. 2006 Sep;49(9):2002-9.
30. Gosmanov AR, Gosmanova EO, Kitabchi AE. Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. MDText.com, Inc.; South Dartmouth (MA): May 9, 2021.
31. Kitabchi AE, Murphy MB, Spencer J, Matteri R, Karas J. Is a priming dose of insulin necessary in a low-dose insulin protocol for the treatment of diabetic ketoacidosis? Diabetes Care. 2008 Nov;31(11):2081-5.
32. Umpierrez GE, Latif K, Stoever J, Cuervo R, Park L, Freire AX, E Kitabchi A. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med. 2004 Sep 01;117(5):291-6.
33. Razavi Z, Maher S, Fredmal J. Comparison of subcutaneous insulin aspart and intravenous regular insulin for the treatment of mild and moderate diabetic ketoacidosis in pediatric patients. Endocrine. 2018 Aug;61(2):267-274.
34. Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. Metabolism. 2016 Apr;65(4):507-21.
35. Pasquel FJ, Umpierrez GE. Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. Diabetes Care. 2014 Nov;37(11):3124-31.
36. Herpes virus fingerprinting. Lancet. 1979 Feb 03;1(8110):251-2.
37. Fayfman M, Pasquel FJ, Umpierrez GE. Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Med Clin North Am. 2017 May;101(3):587-606.
38. Duhon B, Attridge RL, Franco-Martinez AC, Maxwell PR, Hughes DW. Intravenous sodium bicarbonate therapy in severely acidotic diabetic ketoacidosis. Ann Pharmacother. 2013 Jul-Aug;47(7-8):970-5.
39. Glaser N, Barnett P, McCaslin I, Nelson D, Trainor J, Louie J, Kaufman F, Quayle K, Roback M, Malley R, Kuppermann N., Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med. 2001 Jan 25;344(4):264-9.
40. Osuka A, Matsuoka T, Idoguchi K. Is this the worst outcome of metabolic syndrome? Hypophosphatemia and resulting cardiac arrest during the treatment of diabetic ketoacidosis with hypertriglyceridemia. Intern Med. 2009;48(16):1391-5.
41. Regmi A, Konstantinov NK, Agaba EI, Rohrscheib M, Dorin RI, Tzamaloukas AH. Respiratory Failure in the Course of Treatment of Diabetic Ketoacidosis. Clin Diabetes. 2014 Jan;32(1):28-31.
42. Abbas Q, Arbab S, Haque AU, Humayun KN. Spectrum of complications of severe DKA in children in pediatric Intensive Care Unit. Pak J Med Sci. 2018 Jan-Feb;34(1):106-109.
43. Kutlu AO, Kara C, Cetinkaya S. Rhabdomyolysis without detectable myoglobulinuria due to severe hypophosphatemia in diabetic ketoacidosis. Pediatr Emerg Care. 2011 Jun;27(6):537-8.
44. Konstantinov NK, Rohrscheib M, Agaba EI, Dorin RI, Murata GH, Tzamaloukas AH. Respiratory failure in diabetic ketoacidosis. World J Diabetes. 2015 Jul 25;6(8):1009-23.